Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to TradeZacks Investment Research • 11/08/24
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 11/05/24
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/29/24
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSGlobeNewsWire • 10/15/24
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry DiseaseGlobeNewsWire • 09/23/24
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseGlobeNewsWire • 08/15/24
uniQure: Pullback After Strong Interim Treatment Data Creates Buying OpportunitySeeking Alpha • 08/06/24
uniQure Announces Second Quarter 2024 Financial Results and Provides Company UpdateGlobeNewsWire • 08/01/24
Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?Zacks Investment Research • 07/26/24
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a BetZacks Investment Research • 07/10/24
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?Zacks Investment Research • 07/10/24
Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)Zacks Investment Research • 07/09/24
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's DiseaseGlobeNewsWire • 07/09/24
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MAPRNewsWire • 07/01/24
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's DiseaseGlobeNewsWire • 06/03/24
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 05/07/24